Cardiac birth defects induced by maternal medications

Gideon Koren

doi:10.5114/pcard.2020.94827

eISSN: 2449-6731
ISSN: 2449-6723

Prenatal Cardiology

Current issue Archive About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020

Send email

Copy url:

abstract:

Review paper

Cardiac birth defects induced by maternal medications

Gideon Koren

^{1, 2}

Adelson Faculty of Medicine, Ariel University, Ariel, Israel
Motherisk Israel Program, Shamir Medical Center, Zerifin, Israel

Prenat Cardio 2020; 10(1); 57-61

DOI: https://doi.org/10.5114/pcard.2020.94827

Online publish date: 2020/04/27

View full text Get citation

PlumX metrics:

Cardiovascular malformations form the largest group of congenital anomalies, typically quoted at 0.8% of all live births. Several medicinal drugs have been proven to cause cardiovascular malformations. We discuss here the risks of the major known medications, including lithium, valproic acid, ondansetron, methylphenidate, topiramate, and the newly recognised dydrogesterone. In contrast, we discuss the controversial and debated effects of selective serotonin reuptake inhibitors (SSR) and selective serotonin norepinephrine reuptake inhibitors (SNRI). Subsequently we describe the principles of counselling pregnant women and those planning pregnancy, who are exposed to these drugs.

keywords:

Cardiac birth defects induced by maternal medications

Gideon Koren 1, 2

lithium, ondansetron, cardiac malformations, maternal medications, dydrogesterone

Gideon Koren

^{1, 2}